WuXi fallout reverberates; Pharma’s top R&D spenders; Lilly teams up with Amazon; Historic NASH approval; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Boast­ing alert: We learned just a few days ago that End­points News won a gen­er­al ex­cel­lence award from the So­ci­ety for Ad­vanc­ing Busi­ness Edit­ing and Writ­ing. It’s a de­light­ful recog­ni­tion of the team’s hard work. A big thank you to the sub­scribers and part­ners who sup­port us — we couldn’t do it with­out you.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.